Mikkael Sekeres, MD
Hematology & Oncology · Miami, FLNPI 1497710941
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $233,051 of the $277,943 with a category attached, or 83.8%. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2020 at $93,833 and has fallen 79.1% since, to $19,632 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $2028.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$58K
- AstraZeneca$31K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Novartis$25K
- Daiichi Sankyo Inc.$23K
- Eli Lilly$22K
- plus $92K from 17 others
Across 100 payments — averaging $14,550 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$664K
- Bristol Myers Squibb$332K
- Rigel Pharmaceuticals, Inc.$240K
- Takeda Pharmaceuticals U.S.A., Inc.$142K
- Novartis$54K
- Daiichi Sankyo Inc.$22K
- plus $1K from 1 others
What the payments were for
- Consulting fees$233,05184%
- Speaking & faculty fees$15,1405%
- Travel & lodging$17,8236%
- Food & beverage$2,7391%
- Education$9,1903%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 21 | $57,732 |
| AstraZeneca | 7 | $30,816 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $26,866 |
| Novartis | 7 | $24,647 |
| Daiichi Sankyo Inc. | 11 | $23,372 |
| Eli Lilly | 29 | $22,236 |
| GSK | 2 | $20,000 |
| E.r. Squibb & Sons, L.L.C. | 4 | $15,845 |
| Pfizer | 12 | $14,810 |
| Merck | 4 | $14,136 |
| Agios Pharmaceuticals, Inc. | 7 | $7,377 |
| Gilead | 3 | $5,915 |
| Secura Bio, Inc. | 1 | $5,600 |
| Karyopharm Therapeutics Inc. | 5 | $2,626 |
| Beigene USA, Inc. | 1 | $2,275 |
| Amgen | 1 | $1,650 |
| Boehringer Ingelheim | 1 | $1,110 |
| Genmab U.S., Inc. | 4 | $329 |
| Stemline Therapeutics Inc. | 2 | $277 |
| Astellas Pharma US Inc | 1 | $122 |
| Morphosys, US Inc. | 1 | $121 |
| Geron Corporation | 1 | $51 |
| Incyte Corporation | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$277,943 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 12 | $224,745 |
| VenclextaVenetoclax | 46 | $143,211 |
| Imatinib Mesylate | 27 | $124,834 |
| RevlimidLenalidomide | 12 | $109,901 |
| Cyclosporine ModifiedCyclosporine, Modified | 22 | $1,957 |
| Levofloxacin | 12 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $24,647 | $224,74512 claims |
| Bristol Myers SquibbRevlimid | $57,732 | $109,90112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
- Gerald SoffMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.